A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by the complicated and coordinated actions of pro-angiogenic factors and their receptors that become upregulated during tumorigenesis. Over the past several decades, vascular endothelial growth factor (VEGF) signaling has been identified as a central axis in tumor angiogenesis. The remarkable advent of recombinant antibody technology has led to the development of bevacizumab, a humanized antibody that targets VEGF and is a leading clinical therapy to suppress tumor angiogenesis. However, despite the clinical efficacy of bevacizumab, its significant side effects and drug resistance have raised concerns necessitating the identification of novel drug targets and development of novel therapeutics to combat tumor angiogenesis. This review will highlight the role and relevance of VEGF and other potential therapeutic targets and their receptors in angiogenesis. Simultaneously, we will also cover the current status of monoclonal antibodies being developed to target these candidates for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, the suppression of the vascular endothelial growth factor receptor (VEGFR) activation and the complement cascade activation in the RPE and choroid by repeated intravitreal antibody injections is successfully used in clinical studies [204].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [204]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 222 · Cited by 161
Research works printed but not linked: 1
- Andre, 2013, Aflibercept (zaltrap (®)) approved in metastatic colorectal cancer, Bull Cancer, 100, 1023
Metadata
- Authors
- Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S.
- Affiliations
- Scripps Korea Antibody Institute (KR)
- Corresponding author
- Na, Hee-Jun
- Lee, Sukmook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-08-17
- Volume
- 18
- Issue
- 8
- Pages
- 1786
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5578174
- OpenAlex
- W2748749383
- Cited by
- 161
- References
- 222
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 16 · 2023: 12 · 2022: 22 · 2021: 16 · 2020: 33 · 2019: 31 · 2018: 15 · 2017: 2
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- the Scripps Korea Antibody Institute (10TS03)
- the Bio & Medical Technology Development Program of the National Research Foundation (2015M3A9 D9074279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- anti-angiogenic therapy, tumor angiogenesis, VEGF signaling, monoclonal antibodies, bevacizumab, VEGF receptors, humanized monoclonal antibody, drug resistance, novel therapeutic targets, cancer therapy
- MeSH terms
- Bevacizumab, Humans, Immunotherapy, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. https://app.cochat.ai/papers/10.3390/ijms18081786
- The paper
- Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017). A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18081786
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.